Today, the FDA approved Amgen’s AVSOLA (infliximab-axxq), a biosimilar to Janssen’s REMICADE. AVSOLA has the same approved indications label as its reference product.
AVSOLA is the third biosimilar to REMICADE to receive FDA approval, after INFLECTRA and RENFLEXIS, and the 26th FDA-approved biosimilar overall.